VIA Disc NP Registry

May 8, 2024 updated by: VIVEX Biologics, Inc.
Registry is to observe and trend patterns of care and outcomes for patients treated with VIA Disc NP.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The Registry is intended to collect data for patients having received treatment with VIA Disc NP.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
83

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • United States
    • Arizona
      • Mesa, Arizona, United States, 85206
        • Gateway Pain Solutions
    • California
      • Santa Monica, California, United States, 90403
        • Source Healthcare
      • Walnut Creek, California, United States, 94598
        • Interventional Pain Management
    • Colorado
      • Englewood, Colorado, United States, 80112
        • MD Pain
      • Grand Junction, Colorado, United States, 81505
        • Western Rockies Interventional Pain Specialists
      • Greenwood Village, Colorado, United States, 80111
        • The Denver Spine & Pain Institute
    • District of Columbia
      • Washington, District of Columbia, United States, 20006
        • International Spine, Pain & Performance Center
    • Florida
      • Gainesville, Florida, United States, 32607
        • The Orthopedic Institute
      • Port Charlotte, Florida, United States, 33948
        • Southwest Florida Pain Center
      • Tampa, Florida, United States, 33614
        • Florida Spine & Pain Specialists
      • Tampa, Florida, United States, 33609
        • FAST MD
      • Wesley Chapel, Florida, United States, 33544
        • Florida Pain Medicine
    • Indiana
      • Indianapolis, Indiana, United States, 46278
        • Orthopaedic Research Foundation
    • Louisiana
      • Lafayette, Louisiana, United States, 70508
        • Anesthesiology & Pain Consultants
      • Opelousas, Louisiana, United States, 70570
        • Interventional Pain Specialists
    • Michigan
      • Brownstown, Michigan, United States, 48183
        • Michigan Interventional Pain Center
      • Ypsilanti, Michigan, United States, 48198
        • Forest Health
    • Nevada
      • Reno, Nevada, United States, 89511
        • Nevada Advanced Pain Specialists
    • New York
      • New York, New York, United States, 10022
        • Ainsworth Institute of Pain Management
    • North Carolina
      • Asheville, North Carolina, United States, 28803
        • Premier Pain Solutions
      • New Bern, North Carolina, United States, 28560
        • Crystal Coast Pain Management
    • Ohio
      • Loveland, Ohio, United States, 45140
        • Premier Pain
    • Oklahoma
      • Tulsa, Oklahoma, United States, 74133
        • Invictus Healthcare System
    • Pennsylvania
      • Chadds Ford, Pennsylvania, United States, 19317
        • Center for Interventional Pain Spine
    • South Carolina
      • Conway, South Carolina, United States, 29526
        • Atlantic Coast Pain Management
      • Mount Pleasant, South Carolina, United States, 29464
        • Southeastern Spine Institute
    • Tennessee
      • Chattanooga, Tennessee, United States, 37404
        • Specialist in Pain Management
      • Franklin, Tennessee, United States, 37067
        • Vertex Spine
    • Texas
      • North Richland Hills, Texas, United States, 76182
        • Ortho Spine Surgery Institute
      • San Antonio, Texas, United States, 78229
        • MD SpineCare and DC Medical Solutions
      • San Antonio, Texas, United States, 78258
        • Advanced Spine and Pain Center
      • Shenandoah, Texas, United States, 77384
        • The Sprintz Center for Pain

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Registry will include at least 10,000 patients diagnosed with and treated for back pain across approximately 200 selected sites.

Description

Inclusion Criteria:

  • 18 years of age or older
  • Understand and sign the informed consent form (as applicable)
  • VIA Disc NP injection is scheduled for 1 or more levels

Exclusion Criteria:

  • VIA Disc NP injection is not performed

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
VIA Disc NP
Patients meeting study criteria receiving Vivex VIA Disc NP injection as treatment
Other: VIA Disc NP (HCT/P)
VIA Disc NP - Allograft tissue injection

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Patient self-reported back pain
Time Frame: 1, 3, 6, 12, 24, & 36 months
Change in Numeric Rating Scale (NRS) scores. Eleven point pain scale used for patient self-reporting of back pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable).
1, 3, 6, 12, 24, & 36 months
Patient self-reporting of daily function
Time Frame: 1, 3, 6, 12, 24, & 36 months
Change in scores from Oswestry Disability Index (ODI). An index comprising of ten categories of function to quantify disability due to back pain.
1, 3, 6, 12, 24, & 36 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Patient self-reported mental health
Time Frame: 1, 3, 6, 12, 24, & 36 months
Change in patient reported anxiety and depression scores. Four question scale used for patient self-reporting of anxiety and depression which ranges from 0-2 (normal), mild (3-5), moderate (6-8), and severe (9-12).
1, 3, 6, 12, 24, & 36 months
Resource Utilization
Time Frame: 1, 3, 6, 12, 24, & 36 months
Patient reported assessment of healthcare and resources utilized questions to treat ongoing back pain post treatment.
1, 3, 6, 12, 24, & 36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
VIVEX Biologics, Inc.

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Talosix

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Lisa Finstein, MHA, Vivex Biologics

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 3, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 5, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 5, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 3, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 1, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 3, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 10, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 8, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • VIV-001-020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings